ロード中...

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

The combination of targeted therapy with BRAF and MEK inhibitors has become the standard of care in patients with BRAF(V600E) mutant melanoma, but responses are not durable. In addition, the impressive clinical benefits with anti-PD-1 and anti-PD-L1 antibodies (Ab) in patients with heavily pretreate...

詳細記述

保存先:
書誌詳細
出版年:Oncoimmunology
主要な著者: Homet Moreno, Blanca, Mok, Stephen, Comin-Anduix, Begonya, Hu-Lieskovan, Siwen, Ribas, Antoni
フォーマット: Artigo
言語:Inglês
出版事項: Taylor & Francis 2015
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006894/
https://ncbi.nlm.nih.gov/pubmed/27622011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1052212
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!